Swedish Orphan Biovitrum AB reported a third quarter loss of 2.89 billion Swedish kronor, with a loss per share of 8.32 kronor. Adjusted EBITA was up 24% at 3.67 billion kronor, and total revenue increased by 13% to 7.78 billion kronor. The company now expects revenue to grow at a low double-digit percentage for 2025, with an adjusted EBITA margin in the mid-to-high 30s percentage range. Revenue from the strategic portfolio grew by 39% to 5.00 billion kronor. Visit rttnews.com for more earnings news and updates.

Read more at Nasdaq: Sobi Q3 Adj. EBITA Rises